Alkermes (NASDAQ:ALKS) Given New $57.00 Price Target at Royal Bank Of Canada

Alkermes (NASDAQ:ALKS) had its price objective boosted by Royal Bank Of Canada from $56.00 to $57.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other equities research analysts also recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Alkermes in a report on Monday, September 21st. Stifel Nicolaus reiterated a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. The Goldman Sachs Group started coverage on shares of Alkermes in a research note on Thursday, September 24th. They issued a “neutral” rating and a $50.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Finally, HC Wainwright upped their price target on shares of Alkermes from $43.00 to $50.00 and gave the company a “neutral” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.06.

Alkermes Stock Performance

Shares of ALKS opened at $45.89 on Wednesday. Alkermes has a 1 year low of $27.00 and a 1 year high of $55.67. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.47 and a quick ratio of 1.85. The stock’s fifty day moving average price is $43.86 and its two-hundred day moving average price is $40.66. The firm has a market cap of $7.70 billion, a PE ratio of 1,523.00 and a beta of 0.32.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.17. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The company had revenue of $480.13 million during the quarter, compared to the consensus estimate of $463.48 million. During the same quarter in the prior year, the company earned $0.49 EPS. The firm’s quarterly revenue was up 21.8% compared to the same quarter last year. On average, equities research analysts forecast that Alkermes will post -0.57 EPS for the current year.

Insider Activity at Alkermes

In other Alkermes news, EVP David Gaffin sold 2,035 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president owned 219,353 shares in the company, valued at $10,127,528.01. This trade represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the transaction, the executive vice president owned 65,389 shares of the company’s stock, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 22,679 shares of company stock worth $1,070,940. 4.59% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alkermes

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC bought a new position in shares of Alkermes in the third quarter valued at approximately $25,000. Ameritas Advisory Services LLC purchased a new position in Alkermes during the second quarter valued at approximately $39,000. Versant Capital Management Inc grew its stake in Alkermes by 33.9% during the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after acquiring an additional 366 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in Alkermes during the 2nd quarter worth approximately $82,000. Finally, C M Bidwell & Associates Ltd. bought a new stake in Alkermes during the 2nd quarter worth approximately $104,000. 95.21% of the stock is currently owned by institutional investors.

Trending Headlines about Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Alkermes reported third-quarter EPS of $0.09, versus analysts’ expectation of a $0.08 loss, and revenue of $480.1 million, ahead of the $463.5 million consensus and up 21.8% year over year. Article: Alkermes Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its price target from $56 to $57 and maintained an outperform rating, signaling continued analyst confidence. Royal Bank of Canada ratings
• Positive Sentiment: The company reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton around mid-2027, offering a defined pipeline milestone. Article: Alkermes reiterates sales outlook and Phase III timing
• Neutral Sentiment: HC Wainwright lifted its target from $43 to $50 but kept a neutral rating, reflecting a higher valuation estimate without a more bullish recommendation. HC Wainwright ratings
• Neutral Sentiment: EVP David Gaffin sold 2,035 shares, about 0.92% of his holdings. The transaction was made under a pre-arranged Rule 10b5-1 plan, making it less indicative of a fresh change in his outlook. Article: Insider share sale
• Negative Sentiment: Despite the beat, third-quarter profit was reported at $16 million and EPS fell from $0.49 a year earlier. A separate analysis also raised concerns that the shares may be overvalued following the ALKS 7290 trial launch. Article: Lower Q3 profit Article: Valuation concerns

Alkermes Company Profile

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.